Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants

Bin TU; Huiyuan WANG; Xinran AN; Jingkun QU; Qianqian LI; Yanrong GAO; Mingjie SHI; Hong QIU; Yongzhuo HUANG

Bin TU; Huiyuan WANG; Xinran AN; Jingkun QU; Qianqian LI; Yanrong GAO; Mingjie SHI; Hong QIU; Yongzhuo HUANG.

Acta Pharmaceutica Sinica B ; (6): 3187-3194, 2022.

Article in English | WPRIM (Western Pacific) | ID: wpr-939921

Responsible library: WPRO

ABSTRACT

ABSTRACT

The heparin polysaccharide nanoparticles block the interaction between heparan sulfate/S protein and inhibit the infection of both wild-type SARS-CoV-2 pseudovirus and the mutated strains through pulmonary delivery.Image 1.

Delta variant; Heparan sulfate; Heparin nanoparticle; Pulmonary delivery; SARS-CoV-2; Spike protein

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Database: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2022 Document type: Article

Fulltext

Add to My VHL

XML

Search on Google

Full text: Available Database: WPRIM (Western Pacific) Language: English Journal: Acta Pharmaceutica Sinica B Year: 2022 Document type: Article